Description
SWOT ANALYSIS OF SHIONOGI
Shionogi
Parent Company
Shionogi & Co
Category
Pharmaceuticals
Sector
Health care
Tagline/ Slogan
There is a SONG within SHIONOGI; Making a difference in peoples life
USP
It is one of the leading Japanese pharmaceutical company
STP
Segment
Prescription drugs, OTC drugs, diagnostics
Target Group
Buyers of pharmaceutical, diagnostics, and other related products
Provide remedy of the best probable kind vital for protection of the Positioning health of the people.
SWOT Analysis
1.Strong manpower with nearly 6500 employees and a strong revenue 2.Strong distribution network within Japan, Honkong and China 3. Strong product pipeline with majority product in late stages of development 4. Approval of Rapiacta by Japanese drug authority which will boost up the sales Strength 5. Stable financial position and strong brand value
1. Majorly dependant on Japan and US for its sale of drugs. 2. They have limited presence in emerging markets like India, South Africa etc Weakness 3. Less presence in the Oncology market as compared to leaders
1.Innovations in research through outside alliances with academic world and bioventures 2.Widen the manufacturing infrastructure and technology base Opportunity 3.Increase in the CSR related activities
1.Large number of regulatory approvals for sale and distribution in foreign countries 2. Frequent occurrence of natural calamities in Japan like Earthquakes Threats 3. Global economic slowdown
Competition
1. Takeda Pharmaceutical 2. Astellas 3. Daiichi Sankyo Competitors 4. Forest Laboratories
doc_153661296.docx
SWOT ANALYSIS OF SHIONOGI
Shionogi
Parent Company
Shionogi & Co
Category
Pharmaceuticals
Sector
Health care
Tagline/ Slogan
There is a SONG within SHIONOGI; Making a difference in peoples life
USP
It is one of the leading Japanese pharmaceutical company
STP
Segment
Prescription drugs, OTC drugs, diagnostics
Target Group
Buyers of pharmaceutical, diagnostics, and other related products
Provide remedy of the best probable kind vital for protection of the Positioning health of the people.
SWOT Analysis
1.Strong manpower with nearly 6500 employees and a strong revenue 2.Strong distribution network within Japan, Honkong and China 3. Strong product pipeline with majority product in late stages of development 4. Approval of Rapiacta by Japanese drug authority which will boost up the sales Strength 5. Stable financial position and strong brand value
1. Majorly dependant on Japan and US for its sale of drugs. 2. They have limited presence in emerging markets like India, South Africa etc Weakness 3. Less presence in the Oncology market as compared to leaders
1.Innovations in research through outside alliances with academic world and bioventures 2.Widen the manufacturing infrastructure and technology base Opportunity 3.Increase in the CSR related activities
1.Large number of regulatory approvals for sale and distribution in foreign countries 2. Frequent occurrence of natural calamities in Japan like Earthquakes Threats 3. Global economic slowdown
Competition
1. Takeda Pharmaceutical 2. Astellas 3. Daiichi Sankyo Competitors 4. Forest Laboratories
doc_153661296.docx